Pancreatic Cancer Research

ResearcherPeking UniversityActive in the last 2 years

Yinmo Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8781-1022; OpenAlex author ID A5004905094. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 7 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 18

  1. Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy. Co-author DOI 10.1016/j.isci.2026.116029↗
  2. Immune decoding from a multi-omics perspective: Redefining pancreatic cancer tumor microenvironment. First author DOI 10.21147/j.issn.1000-9604.2026.03.08↗
  3. Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single-center retrospective study in … Last author DOI 10.1002/acm2.70092↗
  4. Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1002/advs.202308637↗
  5. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. Last author DOI 10.1186/s12967-023-04051-4↗
  6. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215834↗
  7. Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets. Co-author DOI 10.1093/hmg/ddab343↗
  8. Emerging Role of Exosomal-Derived Long Noncoding RNAs in Human PDAC. Last author DOI 10.1159/000520947↗
  9. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling? Co-author DOI 10.1159/000521847↗
  10. Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/genes13101760↗
  11. Crosstalk between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in the Tumor Microenvironment Mediated by Exosomal MicroRNAs. First author DOI 10.3390/ijms23179512↗
  12. Hypoxic pancreatic cancer derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. Co-author DOI 10.7150/ijbs.67675↗
  13. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. Last author DOI 10.1016/j.ebiom.2021.103315↗
  14. Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. Co-author DOI 10.1126/sciadv.abh2724↗
  15. The Role of Exosomes in Pancreatic Cancer From Bench to Clinical Application: An Updated Review. Last author DOI 10.3389/fonc.2021.644358↗
  16. Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associated with distant recurrence in pancreatic cancer pat… Co-author DOI 10.21037/atm-20-782↗
  17. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer … Last author DOI 10.1021/acsnano.8b01573↗
  18. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Last author DOI 10.1016/j.ejca.2014.05.017↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tian · 12 shared papers, 2014–2026 · strength 2.25
  2. Kai Chen · 8 shared papers, 2021–2024 · strength 1.41
  3. Yongsu Ma · 6 shared papers, 2014–2026 · strength 1.03
  4. Enkui Zhang · 1 shared paper, 2026 · strength 0.63
  5. Long Di · 2 shared papers, 2022 · strength 0.43
  6. Marko Kornmann · 3 shared papers, 2014–2022 · strength 0.40
  7. Zichen Pan · 1 shared paper, 2026 · strength 0.33
  8. Feng Wang · 2 shared papers, 2021–2022 · strength 0.30
  9. Chong Du · 2 shared papers, 2018–2024 · strength 0.27
  10. Guangjun Nie · 2 shared papers, 2018–2024 · strength 0.27
  11. Xiaojuan Du · 1 shared paper, 2025 · strength 0.27
  12. Xiangyu Chu · 1 shared paper, 2022 · strength 0.26
  13. Yazhou Wang · 1 shared paper, 2024 · strength 0.20
  14. Alexander Kleger · 1 shared paper, 2022 · strength 0.17
  15. Helmut Friess · 1 shared paper, 2022 · strength 0.17
  16. Patrick Michl · 1 shared paper, 2022 · strength 0.17
  17. Volker Ellenrieder · 1 shared paper, 2022 · strength 0.17
  18. Di Long · 1 shared paper, 2022 · strength 0.16
  19. Yazhou Wang · 1 shared paper, 2022 · strength 0.16
  20. Huahu Guo · 1 shared paper, 2021 · strength 0.14
  21. Mingzhe Li · 1 shared paper, 2021 · strength 0.14
  22. Weikang Liu · 1 shared paper, 2021 · strength 0.14
  23. Xiu Rong Dong · 1 shared paper, 2020 · strength 0.13
  24. Xiaohang Zhao · 1 shared paper, 2020 · strength 0.13
  25. Zipeng Lu · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.